Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">On The Wires<ul><li>Eurasian Minerals Inc. (<strong>EMX</strong>) provides an update on the Company's Leeville royalty property that covers portions of Newmont Mining Corporation's underground mining operations in the Northern Carlin Trend. EMX has noted an increase in Leeville royalty revenue and equity gold ounces starting in mid-2016. In addition to royalty income from gold production, the Leeville property also provides the Company with upside exposure to Newmont's ongoing exploration advancements at the Rita K and Full House gold deposits. Newmont expects initial resources for Rita K in 2018, and has already outlined resources at Full House.</li><li>Myovant Sciences (<strong>MYOV</strong>) announced it has initiated a Phase 3 clinical program consisting of two international clinical trials, LIBERTY 1 and LIBERTY 2, to evaluate the safety and efficacy of relugolix in women with heavy menstrual bleeding associated with uterine fibroids. Relugolix is an oral, once-daily, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist that decreases estrogen and progesterone. It will be evaluated with and without low-dose hormonal add-back therapy.</li><li>McDermott International, Inc. (<strong>MDR</strong>) announced it was awarded an offshore pipelay contract in the Middle East. The pipelay contract, sizeable in value, includes the engineering, procurement and installation of two oil pipelines offshore. Work on this contract is expected to be completed by the end of the second quarter in 2018.</li><li>The Medicines Company (<strong>MDCO</strong>) announced that full safety and efficacy data from the ORION-1 Phase 2 study of inclisiran, with six- to nine-month follow-up for all patients in the study, will be presented at the American College of Cardiology's 66th Annual Scientific Session (ACC.17), to be held March 17-19, 2017, in Washington D.C. The ORION-1 study will be presented in the «Late-Breaking Clinical Trials — Featured Clinical Research 1» session at 1:30 p.m., Eastern time, on Friday, March 17, 2017, by the ORION-1 principal investigator, Kausik K. Ray, M.D., MPhil (Cantab), FRCP, Professor of Public Health, Imperial College London.</li><li>Camber Energy (<strong>CEI</strong>) updated its operational activity in its recently acquired assets in Oklahoma. «We are pleased with the results of our well performance upgrades, and we plan to apply similar techniques to other wells in the area,» said Anthony C. Schnur, the CEO of Camber Energy. «As we ramp-up production on our legacy and newly-acquired assets, we will also continue to aggressively pursue acquisition opportunities that target both producing and nonproducing reserves located in or near our existing leaseholds. We continue to work with our Board of Directors, and our senior lender to establish our 2017 CAPEX and drilling program. At this point, we would expect to continue an aggressive field enhancement program in our Oklahoma properties gearing up to commence drilling operations in our newly acquired Permian assets in the second half of 2017. Obviously, increasing our production and cash flow in our Oklahoma properties enhances our ability to drill additional well locations both in Oklahoma and Texas. We hope to have more details on our 2017 CAPEX program in the coming weeks,» Mr. Schnur concluded.</li></ul></td> </tr></table>"